Clinical trial • Phase I • Oncology
Vididencel for Chronic myeloid leukemia (chronic phase)
Phase I trial of Vididencel for Chronic myeloid leukemia (chronic phase). open-label. 24 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Chronic myeloid leukemia (chronic phase)
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-11-2025
- First CTIS Authorization Date
- 31-03-2026
Trial design
open-label Phase I trial across 1 site in Norway.
- Open Label
- Yes
- Target Sample Size
- 24
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
Norway
- Earliest CTIS Part Ii Submission Date
- 22-03-2026
- Latest Decision Or Authorization Date
- 31-03-2026
- Processing Time Days
- 9
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Helse Bergen HF
- Department Name
- Department of Medicine
- Principal Investigator Name
- Bjørn Tore Gjertsen
- Principal Investigator Email
- bjorn.tore.gjertsen@helse-bergen.no
- Contact Person Name
- Bjørn Tore Gjertsen
- Contact Person Email
- bjorn.tore.gjertsen@helse-bergen.no
Sponsor
Primary sponsor
- Full Name
- Mendus B.V.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Vididencel
Related trials
Other published trials that may interest you.
- Pioglitazone for Chronic myeloid leukemia (chronic phase)
- OLVEREMBATINIB for Chronic myeloid leukemia (chronic phase)
- Imatinib for Chronic myeloid leukemia (chronic phase)
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer